Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b) As announced in a press release on October 29, 2018, Todd S. Young resigned from his
position as Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc. (the Company), effective October 31, 2018.
(c) On November 2, 2018, the Board of Directors of the Company (the Board) appointed Stephen R. Davis, the Companys Chief Executive
Officer, as the Companys principal financial officer. Mr. Davis biographical and compensation information is available in the Companys prior filings with the Securities and Exchange Commission, including its Definitive Proxy
Statement filed April 30, 2018. While Mr. Davis was appointed as the Companys principal financial officer, the Board appointed Elena Ridloff as the Companys interim Chief Financial Officer. Ms. Ridloff currently serves as
the Companys Senior Vice President, Investor Relations, and will continue to serve in such capacity while performing her duties as the interim Chief Financial Officer.
In addition, on November 2, 2018, the Board appointed Eric Miller, the Companys Controller, as the Companys principal
accounting officer. Mr. Miller, age 39, has been with ACADIA since May 2014. Mr. Miller has held various corporate finance and accounting roles of increasing responsibility at ACADIA, including Financial Reporting Manager and Director of
Financial Planning and Analysis. Prior to joining ACADIA, Mr. Miller worked at Cadence Pharmaceuticals (Cadence) from April 2012 until its acquisition by Mallinckrodt Pharmaceuticals in February 2014, most recently serving as
Manager, Finance. Prior to Cadence, Mr. Miller was employed with RSM US LLP, a public accounting firm, and served as a financial marketing analyst with Jack in the Box Inc. Mr. Miller earned a bachelors degree in Business
Administration from Carnegie Mellon University and is a certified public accountant in the State of California..